Portal Hypertension Management Market Competitive Landscape 2024-2033 – Major Players and Strategies

Overview and Scope
The portal hypertension management market consists of revenues earned by entities by provide services such as medical management, endoscopic therapy, interventional radiology procedures, and monitoring and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The portal hypertension management market also includes sales of nonselective beta-blockers, and vasoconstrictors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Sizing and Forecast
The portal hypertension management market size has grown strongly in recent years. It will grow from $2.88 billion in 2023 to $3.07 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%.  The  growth in the historic period can be attributed to the increased prevalence of liver diseases, growth in the geriatric population, awareness and screening programs, economic burden of liver diseases, approval done for new drugs and therapies, and improvement done for diagnostic methods.

The portal hypertension management market size is expected to see strong growth in the next few years. It will grow to $3.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%.  The growth in the forecast period can be attributed to rising investment in healthcare infrastructure, broader health insurance coverage, favorable regulatory environments and expedited approval processes, ongoing r&d activities focused on understanding the pathophysiology of portal hypertension, and remote monitoring technologies will facilitate continuous patient management. Major trends in the forecast period include growing adoption of telemedicine, continued advancements in medical technology, such as bio-engineered liver tissue, growth in personalized medicine, development of targeted therapies tailored to individual patient profiles, improved diagnostic methods, including non-invasive imaging technologies like elastography.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/portal-hypertension-management-global-market-report

Segmentation & Regional Insights
The portal hypertension management market covered in this report is segmented –
1) By Treatment Type: Medications, Non-Surgical Procedures, Surgery
2) By Procedure Type: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Other Procedure Types
3) By End-User: Hospitals, Specialty Clinics, Other End-Users

North America was the largest region in the portal hypertension management market in 2023. The regions covered in the portal hypertension management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16515&type=smp

Major Driver Impacting Market Growth
An increasing prevalence of liver diseases such as hepatitis is expected to propel the growth of the portal hypertension management market going forward. Liver disease refers to a range of conditions that affect the liver's structure or function, often leading to symptoms such as jaundice, fatigue, and abdominal pain, with causes including viral infections, alcohol abuse, or metabolic disorders. Liver diseases are occurring due to alcohol consumption, viral hepatitis infections, obesity-related fatty liver disease, and metabolic disorders. Portal hypertension management in liver disease aims to reduce pressure in the portal vein system, which helps alleviate complications such as variceal bleeding, ascites, and hepatic encephalopathy, improving patient outcomes. For instance, in September 2022, according to Cancer Australia, an Australia-based government cancer agency, around 2,905 new cases of liver cancer were diagnosed in Australia in 2022 (2,113 males and 792 females). Further, the risk of developing liver cancer by age 85 is predicted to be 1 in 103 (or 0.97%) in 2022, 1 in 70, or 1.4%, for men, and 1 in 195, or 0.51%, for women. Therefore, the increasing prevalence of liver diseases is driving the portal hypertension management market.

Key Industry Players
Major companies operating in the portal hypertension management market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Merck & Co., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals LLC., Lupin Ltd., Daiichi Sankyo, Dr. Falk Pharma GmbH, Cumberland Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Chiasma Inc., Debiovision Inc.

The portal hypertension management market report table of contents includes:
1. Executive Summary
2. Portal Hypertension Management Market Characteristics
3. Portal Hypertension Management Market Trends And Strategies
4. Portal Hypertension Management Market - Macro Economic Scenario
5. Global Portal Hypertension Management Market Size and Growth
……………..
32. Global Portal Hypertension Management Market Competitive Benchmarking
33. Global Portal Hypertension Management Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Portal Hypertension Management Market
35. Portal Hypertension Management Market Future Outlook and Potential Analysis
36. Appendix